Thesis: Medpace is the standout laggard — a great, accelerating business at a de-rated multiple. Unlike the cash-burning AI-bio options (ABCL/GENB), this is a profitable, no-debt, founder-led compounder whose numbers never got the funding-winter memo. If you buy one name in this thesis that hasn't already run, this is the one.

Setup (tape 2026-06-04, code-computed summary)

$456.41, RSI 59, +9% 30d, −2% 3m, −27% from 52wk high (~$625); weak-up. A laggard — only −2% on 3m while the mid-cap tools melted up — but not washed out (RSI 59, turning up). The setup is "quality on sale because of a fear that didn't materialize," not "falling knife."

• Entry zone: ~$420–460 (here), adds toward ~$400 (the rising base). You're not chasing — it lagged the lane's run.
• Stop: ~$370 (below the consolidation base; thesis wrong if it loses it on a real bookings rollover).
• Targets: base $560–630 — a re-rate to ~32–35× on ~$17–18 fwd EPS (back toward the prior high) as funding-winter fear unwinds; bull higher if the IPO/funding gate drives a bookings re-acceleration on top of the multiple. PEG ~1.1 today (28× P/E on ~26% growth) leaves real room.

What it is (Massive company)

Full-service clinical CRO (mid-size, ~6,300 employees), founder-led (August Troendle, large insider ownership) — runs trials end-to-end for small/mid biotech, the exact customer that needs the funding window to reopen. Known for the best margins and the most disciplined capital allocation in the CRO group (aggressive buybacks). Its backlog/book-to-bill is a direct read on biotech trial demand → MEDP is the cleanest public proxy for domino #3 (clinical CRO book-to-bill) in the board.

The financials are the whole point (Massive balance/income, through Q1 2026-03-31)

The tell: the bear case for the whole CRO group was "biotech funding winter → trial cancellations → bookings collapse." MEDP's revenue accelerated to +26% YoY through exactly that period. The fear compressed the multiple; the business never confirmed the fear. So you're buying a quality compounder at a discount created by a thesis its own P&L refutes.

Why it's a laggard (and why that's the opportunity)

The de-rate is multiple compression, not earnings disappointment. The market painted MEDP with the funding-winter brush that hit the cashless biotechs and the weaker CROs (FTRE etc.) — but MEDP's customer concentration in well-funded mid-biotech + its share gains kept growth accelerating. As domino #1 (IPO/funding gate) opens, the fear that compressed the multiple reverses, and a 26%-grower with 20% margins and no debt re-rates toward its historical multiple. This is the lane's best risk/reward: quality + growth + a de-rated multiple + a real catalyst.

Watch-fors / catalysts

• Book-to-bill / net new bookings on the next print (~late-Jul/Aug Q2) — the single most important number; >1.2 and rising = the funding cycle is feeding the backlog. A book-to-bill miss is the main risk.
• Biotech IPO/funding flow — more funded biotechs = more trials = MEDP bookings (the direct transmission).
• Multiple re-rate — watch whether the P/E expands back toward 32–35× as fear unwinds; that's most of the upside.
• Risk: a genuine bookings rollover (cancellations spike), or the funding gate slamming shut again, would break the "fear didn't materialize" thesis. Founder selling would also be a flag.

Sources

• Tape: code-computed summary biotech-capital-cycle (2026-06-04).
• Financials: Massive company/balance/income for MEDP (statements through Q1 2026-03-31; saved to data/stocks/MEDP/massive/). Ratios premium-gated (403) — P/E computed from price ÷ TTM EPS.
• Lane context: perspective biotech-capital-cycle (Tier 1 laggard quality; the direct domino-#3 / CRO-book-to-bill proxy).
• Open follow-ups: pull the actual reported book-to-bill + backlog figure from the 10-Q/earnings (massive:filings) to firm the bookings read; analyst mean target to firm the re-rate scenario.